IMRN 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2026

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published two announcements (the “Public Notices”) to the Australian Securities Exchange on August 28, 2026 titled:

-	Appendix 4E Preliminary Final Report
-	FY26 Results Presentation

A copy of the Public Notices is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit<br><br>Number		Description
99.1		Appendix 4E Preliminary Final Report
99.2		FY26 Results Presentation

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: August 28, 2026	By:	/s/ Olga Smejkalova
		Olga Smejkalova
		Company Secretary

3

Exhibit 99.1

Immuron<br>Limited<br><br>Appendix<br>4E<br><br>Preliminary<br>final report

1. Company details

Name<br>of entity:<br><br>ABN:<br><br>Reporting<br>period:<br><br>Previous<br>period:	Immuron<br>Limited<br><br>80<br>063 114 045<br><br>For<br>the year ended 30 June 2026<br><br>For<br>the year ended 30 June 2025

2. Results for announcement to the market

Revenue from ordinary activities	up	5.9	%	to	7,713,601
Loss from ordinary activities after tax attributable to the members of Immuron Limited	down	26.4	%	to	(3,838,699	)
Loss for the year attributable to the members of Immuron Limited	down	26.4	%	to	(3,838,699	)

All values are in US Dollars.

3. Net tangible assets

	Consolidated
	2026		2025
	Cents		Cents
Net tangible asset backing (per security)		3.35		3.45

The calculation of net tangible assets excludes right-of-use assets arising from AASB 16 Leases.

4. Explanation of results

The reported loss after tax of the current financial year of $3,838,699 (2025: $5,215,987) is after fully expensing the company’s research and development expenditure of $1,933,440 incurred during the year (2025: $3,597,296). Of which, $339,819 (2025: $124,164) was funded by the R&D grant from Henry M Jackson Foundation (HJF).

The revenue from contracts with customers for the year was $7,713,601, which is an increase of 5.9% from the prior financial year (2025: $7,287,002), primarily due to the sales increase in the Australian and North American markets for Travelan®. We anticipate that revenues from sales of our Travelan® product will continue to increase in the future.

As at 30 June 2026, the company’s cash position was $9,017,814 (30 June 2025: $2,830,526). The company had trade and other receivables of $1,250,418 (30 June 2025: $1,925,593). This receivables amount includes future receivables from the Australian Government under the R&D Tax Incentive program. The company had other current assets of $258,197 (30 June 2025: $3,486,744).

The preliminary final report follows, with the further details to be included in the audited financial statements to be released by 30 September 2026.

Immuron<br>Limited<br><br>Appendix<br>4E<br><br>Preliminary<br>final report

5. Distributions

No dividends have been paid or declared by the company for the current financial year. No dividends were paid for the previous financial year.

6. Changes in controlled entities

There have been no changes in controlled entities during the year ended 30 June 2026.

7. Details of associates and joint venture entities

		Ownership interest held by<br><br>the Group
		2026			2025
Name of entity	Place of business/country of incorporation		%			%
Ateria Health Limited	United Kingdom		23.61	%		23.61	%

As at 30 June 2026, Immuron has a 23.61% interest in Ateria Health Limited. Immuron is deemed to have significant influence over Ateria Health Limited.

8. Audit

The financial statements of Immuron Limited (the group) are currently in the process of being audited. Audited financial statements along with the independent auditor report for the year end 30 June 2026 is expected to be released by the end of September 2026.

Immuron<br>Limited<br><br>Consolidated<br>statement of profit or loss and other comprehensive income<br><br>For<br>the year ended 30 June 2026
					Consolidated
---	---	---	---	---	---	---	---	---	---	---	---
		Note			2026				2025
						$				$
Revenue<br>from contracts with customers		1				7,713,601				7,287,002
Cost<br>of goods sold						(2,738,529	)			(2,521,903	)
Gross<br>profit						4,975,072				4,765,099
Other<br>income		2				1,011,169				1,411,505
Other<br>(losses)/gains						(285,115	)			12,183
						726,054				1,423,688
Expenses
General<br>and administrative expenses						(4,305,555	)			(4,483,623	)
Research<br>and development expenses						(1,933,440	)			(3,597,296	)
Selling<br>and marketing expenses						(3,471,556	)			(3,452,416	)
Operating<br>loss						(4,009,425	)			(5,344,548	)
Finance<br>income						185,438				135,866
Finance<br>expenses						(14,712	)			(7,305	)
Loss<br>before income tax expense						(3,838,699	)			(5,215,987	)
Income<br>tax expense						-				-
Loss<br>after income tax expense for the year attributable to the members of Immuron Limited						(3,838,699	)			(5,215,987	)
Other<br>comprehensive income/(loss)
Items<br>that may be reclassified subsequently to profit or loss
Exchange<br>differences on translation of foreign operations income/(expense)						16,311				(1,358	)
Other<br>comprehensive income/(loss) for the year						16,311				(1,358	)
Total<br>comprehensive loss for the year						(3,822,388	)			(5,217,345	)
Loss<br>per share for profit attributable to the ordinary equity holders of the company:						Cents				Cents
Basic<br>and diluted loss per share						(1.29	)			(2.26	)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

1

Immuron<br>Limited<br><br>Consolidated<br>statement of financial position<br><br>As<br>at 30 June 2026
		Consolidated
---	---	---	---	---	---	---	---
	Note	2026			2025
			$			$
Assets
Current assets
Cash and cash equivalents			9,017,814			2,830,526
Trade and other receivables	3		1,250,418			1,925,593
Inventories			2,273,848			1,772,363
Other current assets	4		258,197			3,486,744
Total current assets			12,800,277			10,015,226
Non-current assets
Property, plant and equipment			9,325			10,074
Right-of-use assets			183,396			103,876
Inventories			-			666
Total non-current assets			192,721			114,616
Total assets			12,992,998			10,129,842
Liabilities
Current liabilities
Trade and other payables			1,345,485			1,529,435
Employee benefits			409,433			391,503
Lease liabilities			30,606			45,272
Total current liabilities			1,785,524			1,966,210
Non-current liabilities
Employee benefits			42,210			22,722
Lease liabilities			158,937			71,855
Total non-current liabilities			201,147			94,577
Total liabilities			1,986,671			2,060,787
Net assets			11,006,327			8,069,055
Equity
Share capital	5		95,655,688			88,872,756
Reserves	6		479,493			1,639,504
Accumulated losses			(85,128,854	)		(82,443,205	)
Total equity			11,006,327			8,069,055

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

2

Immuron<br>Limited<br><br>Consolidated<br>statement of changes in equity<br><br>For<br>the year ended 30 June 2026
Consolidated	Issued capital	Reserves		Accumulated losses		Total equity
---	---	---	---	---	---	---	---
Balance at 1 July 2024	88,504,043	3,173,797		(78,968,396	)	12,709,444
Loss after income tax expense for the year	-	-		(5,215,987	)	(5,215,987	)
Other comprehensive loss for the year	-	(1,358	)	-		(1,358	)
Total comprehensive loss for the year	-	(1,358	)	(5,215,987	)	(5,217,345	)
Transactions with members in their capacity as members:
Shares issued, net of transaction costs	272,713	-		-		272,713
Options and warrants issued/expensed (net of adjustments)	-	64,755		-		64,755
Options and warrants lapsed/expired	-	(1,741,178	)	1,741,178		-
Performance rights issued/expensed	-	239,488		-		239,488
Performance rights exercised	96,000	(96,000	)	-		-
Balance at 30 June 2025	88,872,756	1,639,504		(82,443,205	)	8,069,055

All values are in US Dollars.

Consolidated		Issued capital			Reserves			Accumulated<br>losses			Total equity
Balance at 1 July 2025		88,872,756			1,639,504			(82,443,205	)		8,069,055
Loss after income tax expense for the year		-			-			(3,838,699	)		(3,838,699	)
Other comprehensive income for the year		-			16,311			-			16,311
Total comprehensive loss for the year		-			16,311			(3,838,699	)		(3,822,388	)
Transactions with members in their capacity as members:
Shares issued, net of transaction costs (note 5)		6,655,572			-			-			6,655,572
Options issued/expensed (note 6)		-			80,237			-			80,237
Options and warrants expired (note 6)		-			(1,153,050	)		1,153,050			-
Performance rights issued/expensed (note 6)		-			213,023			-			213,023
Performance rights exercised (note 6)		249,137			(249,137	)		-			-
Performance rights forfeited (note 6)		-			(67,395	)		-			(67,395	)
Shares cancelled pursuant to the buy-back of unmarketable parcels (note 5)		(121,777	)		-			-			(121,777	)
Balance at 30 June 2026		95,655,688			479,493			(85,128,854	)		11,006,327

All values are in US Dollars.

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

3

Immuron<br>Limited<br><br>Consolidated<br>statement of cash flows<br><br>For<br>the year ended 30 June 2026
	Consolidated
---	---	---	---	---
	2026		2025
Cash flows from operating activities
Receipts from customers (inclusive of GST)	8,479,637		7,592,577
Payments to suppliers (inclusive of GST)	(13,189,690	)	(14,772,687	)
Australian R&D tax incentive refund	1,110,514		768,433
Grants received from government and non-government sources	339,819		274,728
Net cash used in operating activities	(3,259,720	)	(6,136,949	)
Cash flows from investing activities
Payment for property, plant and equipment	(4,752	)	-
Proceeds/payments for term deposit	3,036,278		(3,036,278	)
Interest received	209,126		135,866
Net cash from/(used in) investing activities	3,240,652		(2,900,412	)
Cash flows from financing activities
Proceeds from issues of shares	7,148,698		396,827
Payments for share buy-backs	(121,777	)	-
Share issue transaction costs	(493,126	)	(124,114	)
Principal elements of lease payments	(43,923	)	(65,661	)
Interest and other costs of finance paid	(14,712	)	(7,305	)
Net cash from financing activities	6,475,160		199,747
Net increase/(decrease) in cash and cash equivalents	6,456,092		(8,837,614	)
Cash and cash equivalents at the beginning of the financial year	2,830,526		11,657,315
Effects of exchange rate changes on cash and cash equivalents	(268,804	)	10,825
Cash and cash equivalents at the end of the financial year	9,017,814		2,830,526

All values are in US Dollars.

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

4

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

1. Revenue from contracts with customers

The Group derives revenue from the transfer of hyperimmune products at a point in time in the following major product lines and geographical regions:

	Consolidated
	2026	2025
Hyperimmune products revenue
Travelan - Australia	5,672,501	5,201,385
Travelan - United States	1,768,411	1,658,336
Travelan - Canada	165,669	378,706
Protectyn - Australia	21,799	48,575
ProIBS - Australia	85,221	-
Revenue from external customers	7,713,601	7,287,002

All values are in US Dollars.

2. Other income

	Consolidated
	2026	2025
Australian R&D tax incentive refund (i)	623,613	1,110,577
MTEC R&D grant	-	146,252
HJF R&D grant	339,819	124,164
Other income	47,737	30,512
	1,011,169	1,411,505

All values are in US Dollars.

(i) Fair value of Australian R&D tax incentive

The Group’s research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2026, the Group has included an item in other income of $623,613 (2025: $1,110,577).

3. Trade and other receivables

	Consolidated
	2026		2025
Current assets
Trade receivables	638,773		826,857
Less: Allowance for expected credit losses	(11,968	)	(35,466	)
	626,805		791,391
Accrued income - Australian R&D tax incentive refund	623,613		1,110,514
Other receivables	-		23,688
	1,250,418		1,925,593

All values are in US Dollars.

5

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

3. Trade and other receivables (continued)

Classification as trade receivables

Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The Group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method.

Accrued receivables

These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive.

Fair value of trade and other receivables

Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value.

4. Other current assets

	Consolidated
	2026	2025
Prepayments	258,197	442,800
Term deposits	-	3,036,278
Other current assets	-	7,666
	258,197	3,486,744

All values are in US Dollars.

For the year ended 30 June 2025, the Group entered into a 90-day fixed term deposit, which matured on 27 July 2025. Term deposits are presented as Other Current Assets as they are not considered highly liquid instruments readily convertible to cash and cash equivalents. The deposit was held to maturity in accordance with the Group’s investment policy.

5. Share capital

	Consolidated
	2026		2025		2026		2025
	Shares		Shares
Ordinary shares - fully paid		322,848,081		233,959,013	105,858,005		98,581,947
Transaction costs arising on ordinary share issues					(10,202,317	)	(9,709,191	)
		322,848,081		233,959,013	95,655,688		88,872,756

All values are in US Dollars.

6

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

5. Share capital (continued)

Movements in ordinary shares:

Shares
Opening balance 1 July 2024	227,998,346		88,504,043
Issue of shares on the exercise of performance rights at 0.0 per share (2024-10-07)	1,147,083		83,000
Issue at 2.1784 pursuant to At The Market facility (2025-01-08)	2,579,760		226,567
Issue at 2.0971 pursuant to At The Market facility (2025-01-15)	1,801,680		152,300
Issue of shares on the exercise of performance rights at 0.0 per share (2025-04-10)	179,664		13,000
Issue at 1.8435 pursuant to At The Market facility (2025-05-29)	135,800		9,744
Issue at 1.8286 pursuant to At The Market facility (2025-06-03)	116,680		8,216
Less: Transaction costs arising on share issues			(124,114	)
Balance at 30 June 2025	233,959,013		88,872,756
Issue at 1.8939 pursuant to At the Market facility (2025-07-17)	877,440		63,351
Issue at 1.8782 pursuant to At the Market facility (2025-07-18)	473,880		34,072
Issue at 2.1374 pursuant to At the Market facility (2025-07-21)	32,909,640		2,711,754
Issue at 2.3008 pursuant to At the Market facility (2025-10-20)	1,133,840		100,458
Issue at 1.9631 pursuant to At the Market facility (2025-11-07)	8,495,080		642,228
Issue at 2.0809 pursuant to At the Market facility (2025-12-05)	45,472,000		3,596,835
Issue of shares on the exercise of performance rights at 0.0 per share (2025-12-11)	1,874,964		141,890
Issue of shares on the exercise of performance rights at 0.0 per share (2025-12-15)	1,142,909		83,251
Issue of shares on the exercise of performance rights at 0.0 per share (2025-12-16)	314,843		23,996
Shares cancelled pursuant to the buy-back of unmarketable parcels (2026-06-29)	(3,805,528	)	(121,777	)
Less: Transaction costs arising on share issues			(493,126	)
Balance at 30 June 2026	322,848,081		95,655,688

All values are in US Dollars.

Rights of each type of share

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the company in proportion to the number of shares held. On a show of hands every holder of ordinary shares present at a meeting or by proxy, is entitled to one vote upon a poll every holder is entitled to one vote per share held. The ordinary shares have no par value.

7

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

6. Reserves

Consolidated		Share-based<br>payments			Foreign<br>currency<br>translation			Total
Balance at 1 July 2024		3,059,321			114,476			3,173,797
Currency translation<br>differences		-			(1,358	)		(1,358	)
Options and warrants issued/expensed<br>(net of adjustments)		64,755			-			64,755
Options and warrants lapsed/expired		(1,741,178	)		-			(1,741,178	)
Performance rights issued/expensed		239,488			-			239,488
Performance<br>rights exercised		(96,000	)		-			(96,000	)
Balance at 30 June 2025		1,526,386			113,118			1,639,504
Currency translation differences		-			16,311			16,311
Transactions with owners<br>in their capacity as owners:
Options<br>issued/expensed (note 6)		80,237			-			80,237
Options and warrants expired<br>(note 6)		(1,153,050	)		-			(1,153,050	)
Performance rights issued/expensed<br>(note 6)		213,023			-			213,023
Performance rights exercised<br>(note 6)		(249,137	)		-			(249,137	)
Performance<br>rights forfeited (note 6)		(67,395	)		-			(67,395	)
Balance<br>at 30 June 2026		350,064			129,429			479,493

All values are in US Dollars.

8

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

6. Reserves (continued)

Nature and purpose of other reserves

Share-based payments:

The share-based payment reserve records items recognised as expenses on valuation of share options and warrants issued to key management personnel and other employees.

Foreign currency translation:

Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income and accumulated in a separate reserve within equity.

Movements in options, warrants and performance rights:

Details	Number of<br><br>options,<br><br>warrants and<br><br>rights
Balance as at 1 July 2024		15,194,959		3,059,321
Options issued in the year (net of adjustments)		3,000,000		55,584
Lapse of unexercised options		(8,016,120	)	(1,741,178	)
Share-based payments expense for options previously issued		-		9,171
Performance rights issued in the year		5,386,810		239,488
Exercise of performance rights		(1,326,747	)	(96,000	)
Lapse of performance rights issued in the year		(285,741	)	-
Balance as at 30 June 2025		13,953,161		1,526,386
Warrants expired in the year		(2,560,000	)	(1,032,960	)
Options expired in the year		(1,930,000	)	(120,090	)
Options issued in the year (note 7)		4,000,000		48,995
Share-based payments expense for options previously issued		-		31,242
Performance rights issued in the year		2,147,154		137,418
Exercise of performance rights		(3,332,716	)	(249,137	)
Performance rights forfeited		(510,108	)	(67,395	)
Share-based payments expense for performance rights previously issued		-		75,605
Balance as at 30 June 2026		11,767,491		350,064

All values are in US Dollars.

9

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

7. Share-based payments

Performance rights:

Performance rights, which can be settled in shares, were granted to key management personnel and employees during the period. The performance rights are based on non-market weighted key performance indicators (KPIs) and have been expensed over the service period, based on the probability the KPIs being achieved. The performance rights are expected to vest between one and five years. During the reporting period, assessments are made as to whether KPIs have been met and whether KPIs are likely to be met. As a result of such assessment, there was a net reduction in share-based payment expense during the period.

During the year ended 30 June 2026, 2,147,154 performance rights were granted to employees with a conversion price of $0.145.

Fair value is determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the award, security price at grant date, expected volatility, expected dividend yield and the risk-free interest rate.

The model inputs for the performance rights granted during the year:

Grant date	Expiry<br>date	Exercise price (A)	No. of<br>options		Share price at<br>grant date	Expected<br>volatility			Dividend<br>yield			Risk-free<br>interest rate			Fair value<br>at grant<br>date per option
16-AUG-25	16-AUG-29	0.145		2,147,154	0.070		88.65	%		0.00	%		4.09	%	0.0640

All values are in US Dollars.

Options:

During the year ended 30 June 2026, options were approved at the Annual General Meeting, held on 11 November 2025 for Jeannette Joughin, Daniel Pollock, Ravi Savarirayan, and Paul Brennan of 1,000,000 each. The option exercise price is $0.110 and they have an expiry date of 3 October 2029.

Fair value is determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the award, security price at grant date, expected volatility, expected dividend yield and the risk-free interest rate.

The model inputs for the options granted during the year:

Grant date	Expiry<br><br>date	Exercise<br>price (A)	No. of<br><br>options		Share price at<br>grant date	Expected<br><br>volatility			Dividend<br><br>yield			Risk-free<br>interest rate			Fair value<br>at grant<br>date per<br>option
11-NOV-25	3-OCT-29	0.110		4,000,000	0.060		77.46	%		0.00	%		3.69	%	0.0271

All values are in US Dollars.

8. Events after the reporting period

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group’s operations, the results of those operations, or the Group’s state of affairs in future financial years.

10

Immuron<br>Limited<br><br>Notes<br>to the consolidated financial statements<br><br>30<br>June 2026

9. Principal subsidiaries

The Group’s principal subsidiaries at 30 June 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of business.

		Ownership interest by<br><br>the Group
Name of entity	Principal place of business /<br><br>Country of incorporation	2026<br><br>%			2025<br><br>%
Immuron Inc.	United States		100	%		100	%
Immuron Canada Limited	Canada		100	%		100	%
Anadis ESP Pty Ltd	Australia		100	%		100	%

10. Interests in associates

Immuron Limited has a 23.61% interest in Ateria Health Limited. The carrying amount of the investment continues to be nil, therefore, no share of the loss has been recognised for the year ended 30 June 2026.

		Ownership interest held by<br><br>the Group
Name of entity	Principal place of business /<br><br>Country of incorporation	2026<br><br>%			2025<br><br>%
Ateria Health Limited	United Kingdom		23.61	%		23.61	%

11

Exhibit 99.2

Immuron FY26 Preliminary Results

Melbourne, Australia, August 28, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026.

Results exceed expectations

In February 2026 at the time the Company announced a Strategic Reset, 2H FY26 and FY26 Net Sales were projected to both exceed the prior comparative period (pcp) and Net Sales and Net Profit were all projected to exceed pcp.

Immuron has exceeded sales projections with second half growth of 7% on the prior comparative period (pcp) and record FY26 sales of A$7.7 million, growth of 6% on pcp.

Pleasingly in FY26, the Australian market continued double digit growth (+10%) notwithstanding the one-off impact of Chemist Warehouse/Sigma reducing Travelan® inventories held as a result of their supply chain efficiency initiatives. Sales in the United States continue to grow on the back of a number of marketing initiatives (AUD: +7% on pcp; USD: +13% on pcp). Sales in Canada were down on last year however during the second half of FY26 they were up more than 100% on pcp.

Net Profit in FY26 improved by AUD$1.4 million over FY25. Cash in FY26 increased by AUD$6.2 million^1^ to AUD$9.0 million.

Key milestones achieved

·	IMM-529 (CDI): U.S. FDA approval of investigational<br>new drug (IND) application in November 2025.
·	Uniformed Services University IMM-124E trial<br>reported topline results in December 2025.
---	---
·	New research agreement signed in December 2025<br>funded by a U.S. Department of Defense sub award with the Naval Medical Research Command and Walter Reed Army Institute of Research for<br>the development of novel vaccines targeting Campylobacter and Shigella with which Immuron will produce two hyper-immune bovine colostrum<br>products for pre-clinical evaluation. First revenue was received in May 2026.
---	---
·	In February 2026, Immuron made a strategic decision<br>to partner clinical assets IMM-124E and IMM-529 for development and commercialization.
---	---
o	IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s diarrhea).
---	---
§	Lumanity1 peak U.S. sales estimate of US$102<br>million.
---	---
o	IMM-529 has an investigational new drug (IND) application approved by the U.S. FDA and is ready to go<br>into Phase 2 clinical trials (indication: Clostridioides difficile infection).
---	---
§	Lumanity1 peak U.S. sales estimate of US$400<br>million.
---	---
·	In July 2026, the Company engaged Pullan Consulting<br>to support partnering IMM-529.
---	---
1.	$3.0 million was held in Term Deposits on 30 June 2025 (30<br>June 2026: Nil)
---	---

Looking ahead

In FY27 the Company plans to invest to grow in North America while continuing the momentum in Australia.

Immuron anticipates the following near term milestones:

·	Q1: Continued Travelan® growth
·	Q2: Portfolio expansion
---	---
·	Q3: IMM-529 partnering progress
---	---
·	Q4: Geographic expansion, improved profitability<br>and reduction in cash burn
---	---

A copy of Appendix 4E and the Preliminary Final Report and results presentation are included below.

This release has been authorised by the directors of Immuron Limited.

• • • END - - -

COMPANY CONTACT:

Steven Lydeamore

Chief Executive Officer

[email protected]

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

About Travelan®

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.

Travelers’ diarrhea (TD)

TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).

Immuron Platform Technology

Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

IMM-124E (Travelan®)

IMM-124E was developed using Immuron’s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC. (Otto et al., 2011)

The resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).

The antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core ‘R’ region of LPS from the 13 serotypes used in the ETEC vaccine.

IMM-124E is manufactured into a tablet form referred to as Travelan®.

IMM-529

Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.

Immuron is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.

This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.

To our knowledge, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).

ProIBS®

Immuron has an exclusive distribution agreement with Calmino goup AB for the territories of Australia and New Zealand for ProIBS®. ProIBS® - to help patients treat IBS symptoms ProIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS® contains AVH200®, derived from the plant Aloe barbadensis. Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use –as ProIBS® is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. PROIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu.

Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.(healthdirect.gov.au) According to available data, the IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)

References

Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.

Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5

Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006

Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.

Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers’ (US military and similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.

Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.

Steffen R. Epidemiology of travelers' diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com

Subscribe to Immuron’s InvestorHub: Here

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

11 FY26 PRELIMINARY RESULTS NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO

22 2 Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. SAFE HARBOR STATEMENT FY2026 results in this presentation are subject to audit review.

3 FY26 Financial Achievements Global Sales Revenue $7.7m Up 6% Australian Sales Revenue $5.8m Up 10% United States Sales Revenue $1.8m Up 7% Up 13% in $USD Gross Profit Margin 64.5% 0.9% decline Net Profit $(3.8)m $1.4m improvement Cash $9.0m $6.2m1 improvement 1. $3.0 million was held in Term Deposits on 30 June 2025 (30 June 2026: Nil)

4 FY26 Clinical Achievements and Operational Highlights FDA approval IMM-529 IND Travelan® n=851 trial completed New U.S. Department of Defense subaward New product launch in Australia Engaged Pullan Consulting to support partnering IMM-529 Strategic reset aimed at profitability and reduced cash burn

5 FY27 Outlook Continued Travelan® sales growth Portfolio expansion Geographic sales expansion Partnering update for IMM-529 Cash to fund operations through FY27 – FY28 Continued improvement in profitability and reduced cash burn

EMAIL: [email protected] PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: IMMURON INVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH